Disobutamide

Synonyms: SC-31828
Disobutamide (SC-31828) 是一种口服有效且可透过血脑屏障的阳离子两亲性双叔胺哌啶环化合物,具有抗心律失常特性,可诱导溶酶体磷脂沉积引发广泛的胞质空泡化而导致细胞死亡,会延长犬心脏的多种心电图间期并在高剂量下引发心脏骤停,同时引起视网膜反射率降低,可用于心律失常的相关研究,还可作为模型药物用于探究细胞内两亲性化合物的储存机制及毒性阈值。
产品编号: MS-T23281 CAS No.: 68284-69-5 分子式: C23H38ClN3O 分子量: 408.02
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Disobutamide (SC-31828) 是一种口服有效且可透过血脑屏障的阳离子两亲性双叔胺哌啶环化合物,具有抗心律失常特性,可诱导溶酶体磷脂沉积引发广泛的胞质空泡化而导致细胞死亡,会延长犬心脏的多种心电图间期并在高剂量下引发心脏骤停,同时引起视网膜反射率降低,可用于心律失常的相关研究,还可作为模型药物用于探究细胞内两亲性化合物的储存机制及毒性阈值。

生物实验数据

生物活性 Disobutamide (SC-31828) is an orally effective, blood-brain barrier-permeable cationic amphiphilic bis-tertiary amine piperidine compound with antiarrhythmic properties that induces lysosomal phospholipidosis leading to extensive cytoplasmic vacuolation and cell death, prolongs multiple electrocardiographic intervals in canine hearts and causes cardiac arrest at high doses while reducing retinal reflectivity, and can be used for research related to arrhythmias as well as as a model drug to investigate the storage mechanisms and toxicity thresholds of intracellular amphiphilic compounds.
体外研究
(In Vitro)

Disobutamide (1×10-4-10×10-4 M; 24 h) 不会对大鼠膀胱癌细胞或兔主动脉肌细胞产生显著细胞毒性 (以 LDH 释放为检测指标),但在 ≥4×10-4 M 浓度下,会对大鼠嗜碱性白血病细胞产生严重细胞毒性。
Disobutamide (10-3 M; 24 h) 在大鼠膀胱癌细胞 (RBT CC-8) 中的细胞摄取量会随培养基碱性增强而提升,摄取水平较高时会形成明显的细胞质空泡。
Disobutamide (10-6-10-3 M; 30 min-6 hr) 表现出种属特异性的体外脉络丛组织摄取,其中大鼠脉络丛的摄取量最高,其次是猴脉络丛,然后是犬脉络丛;且在 ≥10-4 M 时可诱导犬脉络丛上皮细胞呈剂量依赖性空泡化。

Cell Cytotoxicity Assay

Cell Line: rat urinary bladder carcinoma (RBT CC-8) cells, rabbit aorta muscle cells, rat basophilic leukaemia cells
Concentration: 1×10-4 M, 2×10-4 M, 4×10-4 M, 6×10-4 M, 8×10-4 M, 10×10-4 M
Incubation Time: 24 h
Result: Caused LDH release relative to total enzyme of ≤5.2% at all tested concentrations in rat urinary bladder carcinoma cells.
Caused LDH release relative to total enzyme ranging from 5.3% at 1×10-4 M to 31.2% at 10×10-4 M in rabbit aorta muscle cells, a magnitude not indicative of cytotoxicity.
Caused LDH release relative to total enzyme of 2.2% at 1×10-4 M, 18.7% at 2×10-4 M, and 84.4-89.9% at 4×10-4 M to 10×10-4 M in rat basophilic leukaemia cells, indicating significant cytotoxicity at concentrations ≥4×10-4 M.
体内研究
(In Vivo)

Disobutamide (6-90 mg/kg/天;口服;每日;14 天-52 周) 可在犬的多种细胞类型和器官中诱导呈剂量/时间依赖性的进行性胞质空泡化,且无明显细胞损伤;同时,高慢性剂量下会引发心脏电生理效应和猝死,而绒毡层改变的未观察到不良反应阈值低于 6 mg/kg/day。
Disobutamide (10-300 mg/kg/天;口服;每日给药;5 天-52 周) 在 300 mg/kg/天剂量下可诱导褐家鼠脉络丛和附睾上皮细胞出现选择性胞质空泡化,相同剂量下长期暴露会引发致死性毒性,且在长期高剂量给药过程中可诱导肝磷脂沉积但无细胞损伤。
Disobutamide (30-250 mg/kg;灌胃;每日;4-35 天) 可在大鼠多个器官中诱导剂量依赖性溶酶体空泡化 (磷脂沉积症),其中 250 mg/kg 剂量下脉络丛上皮空泡化程度极重,100 mg/kg 剂量下为中度改变,30 mg/kg 剂量下为轻度改变。
Disobutamide (45 mg/kg;口服;每日一次;连续 35 天) 会在犬类的多个器官中诱导空泡形成,但不会影响脉络丛上皮细胞;而直接脑室内给药 (0.035 mg;脑室内注射;单次) 会引发脉络丛上皮细胞空泡形成,这与口服给药时药物难以穿透进入脑脊液 (CSF) 有关。
Disobutamide (90 mg/kg;灌胃;每日;35 天) 会引发猕猴脉络丛上皮细胞极为严重的空泡化,以及其他器官的剂量依赖性空泡化,这与脉络丛中药物浓度较高、且脑脊液/血清比值随时间升高相关。

Animal Model: Jcl:SD rats (male and female, 5 weeks of age)
Dosage: 30 mg/kg; 100 mg/kg; 250 mg/kg
Administration: i.g.; daily; 13 weeks (30, 100, 250 mg/kg); i.g.; single dose (100, 250 mg/kg); i.g.; daily; 4, 7, or 35 days (100, 250 mg/kg)
Result: Caused 10/16 males and 10/16 females to die of convulsions during weeks 1-9 at 250 mg/kg.
Reduced feed intake and depressed body weight gain in both sexes at 250 mg/kg.
Elevated total cholesterol in both sexes, phospholipid in males, and triglyceride in females at 250 mg/kg.
Decreased most organ weights in males, and thymus/spleen weights in females at 250 mg/kg.
Induced very severe vacuolation in choroid plexus epithelium, severe vacuolation in renal distal tubules and hepatocytes, moderate vacuolation in submaxillary gland, bronchus, uterine epithelium, cardiac muscle, coronary artery, and lung macrophages, slight vacuolation in stomach, small intestine, spleen macrophages, thymus macrophages, and bone marrow macrophages at 250 mg/kg.
Detected choroid plexus drug concentration of 11.8 mg/g, brain concentration of 26.2 μg/g, liver concentration of 604 μg/g, and kidney concentration of 403 μg/g after 35 days of 250 mg/kg dosing.
Caused muscle relaxation and prone position in females, slight feed intake decrease and body weight gain depression in males, slight thymus weight decrease in males, and slight vacuolation in submaxillary gland, bronchus, cardiac muscle, coronary artery, lung macrophages, thymus macrophages, and bone marrow macrophages at 100 mg/kg.
Induced large lysosome increase in choroid plexus epithelium after 4 days and vacuoles in large choroid plexus lysosomes after 7 days of 100 mg/kg dosing.
Caused slight thymus weight decrease in males and slight vacuolation in submaxillary gland, cardiac muscle, coronary artery, thymus macrophages, and bone marrow macrophages at 30 mg/kg.
Animal Model: Beagle dogs (female, 13-17 months of age; male and female, 10 months of age)
Dosage: 45 mg/kg; 0.035 mg total dose
Administration: p.o.; daily; 35 days (45 mg/kg); i.c.v.; single dose (0.035 mg)
Result: Induced severe vacuolation in stomach, small intestine, renal distal tubules, and bronchial epithelium, moderate vacuolation in spleen macrophages, slight vacuolation in esophagus, submaxillary gland, iris pigment epithelium, hepatocytes, cardiac muscle, coronary artery, aorta, intestinal muscle cells, lung macrophages, thymus macrophages, and bone marrow macrophages at 45 mg/kg p.o.
Detected choroid plexus drug concentration of 0.124 mg/g, brain concentration of 12.2 μg/g, liver concentration of 468 μg/g, and kidney concentration of 653 μg/g after 35 days of 45 mg/kg p.o. dosing.
Caused numerous enlarged lysosomes (some with vacuoles) in choroid plexus epithelial cells 3 hours after 0.035 mg i.c.v. dosing.
Animal Model: Macaca fasciculata (female, adult age)
Dosage: 90 mg/kg
Administration: i.g.; daily; 35 days
Result: Induced severe lymphocyte cytoplasmic vacuolation; one monkey showed elevated total cholesterol and phospholipid at 2 weeks.
Caused very severe vacuolation in choroid plexus epithelium, severe vacuolation in renal distal tubules and intestinal muscle cells, moderate vacuolation in stomach, small intestine, bronchial epithelium, uterine epithelium, hepatocytes, coronary artery, spleen macrophages, and bone marrow macrophages, slight vacuolation in esophagus, submaxillary gland, cardiac muscle, aorta, lung macrophages, and thymus macrophages.
Detected choroid plexus drug concentration of 30.233 mg/g, brain concentration of 18.7 μg/g, liver concentration of 1304 μg/g, and kidney concentration of 1092 μg/g after 35 days of dosing.
Showed higher CSF concentration at 24 hours and significantly higher CSF/serum ratio at 24 hours on day 35 compared to day 1.

化学信息

分子量 408.02
分子式 C23H38ClN3O
CAS No. 68284-69-5
别名 SC-31828

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础